News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Lipodystrophy news

Show

From To
Side-effects
Almost three-quarters of people starting HIV therapy in Tanzania have dyslipidemia after three years of treatment

Approximately 75% of HIV-positive patients in Tanzania had lipid abnormalities three years after starting antiretroviral therapy, research published in the online edition of Clinical Infectious Diseases shows.

Published
28 March 2013
By
Michael Carter
Lipodystrophy
Health Canada rejects tesamorelin for lipodystrophy

After consideration of the NDS, Health Canada decided that the risks of tesamorelin outweighed its benefits under the proposed conditions of use.

Published
13 March 2013
From
Theratechnologies press release
Lipodystrophy
Mark S. King: I'm Gonna Wipe That AIDS Right Off My Face

It was all well and good to be front and center as an HIV-positive man during the first years of the AIDS crisis. It's easier being a role model when your face looks good on the poster. But then, slowly but surely, a common side effect of HIV medications, facial wasting, began to appear.

Published
30 January 2013
From
Huffington Post
Lipodystrophy
The Bio-Alcamid disaster

“Nightmare.” That’s how one man described a weeks-long ordeal involving ad hoc surgery, repeated infections and some hefty out-of-pocket fees – all caused by a device that was once thought to be a miracle for those dealing with the visible signs of HIV.

Published
08 October 2012
From
Xtra
Lipodystrophy
The mirror has two faces - a personal account of using facial filler for lipoatrophy

In the end, for me the few small lumps, the cost of treatment, and the pain were all a small price to pay for what it has ultimately done for my self-esteem. I feel better about myself overall, because I look healthier.

Published
28 September 2012
From
Positively Aware
Lipodystrophy
High rate of infections in people with HIV receiving Bio-Alcamid treatment for facial lipoatrophy

Bio-Alcamid treatment for HIV-related lipoatrophy is associated with a high-rate of infectious complications, Canadian investigators report in the online edition of Clinical Infectious Diseases. The infections typically developed

Published
10 September 2012
By
Michael Carter
Lipodystrophy
Theratechnologies sinks on HIV drug setback

The Committee for Medicinal Products for Human Use in Europe cited potential concerns for long-term users and a lack of data on cardiovascular risks as the reason for its unfavorable view of the drug, Theratechnologies said in a statement.

Published
22 June 2012
From
Reuters
Lipodystrophy
Reductions in visceral fat during tesamorelin therapy associated with improvements in key metabolic markers

Reductions in visceral adiposity achieved with tesamorelin therapy are associated with improvements in some key metabolic parameters, according to a study published in the online edition of

Published
30 April 2012
By
Michael Carter
Side-effects
Why it's time to say goodbye to stavudine...everywhere

Concerns about a proposed comparative trial of 40mg and 20mg (low-dose) stavudine in South Africa.

Published
16 April 2012
From
South African Journal of HIV Medicine
Lipodystrophy
Lipoatrophy common in children receiving d4T in South Africa

Exposure to d4T (stavudine) among young children in sub-Saharan Africa remains the greatest risk factor for lipodystrophy syndrome (that includes lipoatrophy and lipohypertrophy) for a significant proportion of

Published
07 March 2012
By
Carole Leach-Lemens
← Prev12345...7Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.